Jump To Navigation

W. David Wallace GPhA Presentation

W. David Wallace spoke at the GPhA Annual Meeting, held in Naples, Florida on February 23-25, 2009. David's presentation is entitled "Recent FDA Decisions Regarding Forfeiture Of 180-Day Exclusivity" and was given on February 23, 2009.

To see a copy of the presentation click the link below:

GPhA Presentation

To Review the FDA Letters discussed in the presentation click on the link below:


July 31 2006 FDA Letter to Sandoz, Inc. ( Metoprolol Succinate ER)


January 17 2008 FDA Letter to Teva North America (Granisetron Hydrochloride)

February 6 2008 FDA Letter to Perrigo R&D Company (Famotidine/Calcium Carbonate/Magnesium Hydroxide)

February 20 2008 FDA Letter to Watson Laboratories, Inc. (Irinotecan Hydrochloride)

May 7 2008 FDA Letter to Cobalt Pharmaceuticals, Inc. (Acarbose)

October 28 2008 FDA Letter to Hi-Tech Pharmacal Co. (Dorzolamide/Timolol)